Sentences with phrase «vaccine approaches for»

He has made several important contributions in this area including identifying a new strain of CHIKV virus, identification of host cellular targets of HIV accessory genes, new novel DNA vaccine approaches for HIV, CHIKV, RSV, Dengue, MERS and Zika among others.

The second focus on my research is the development of novel therapeutic vaccine approaches for cancer.

«This broad implication is in contrast to a more traditional vaccine - based approach, which requires a specialist to surgically remove tumor samples from a patient's body then create a personalized vaccine approach for one specific patient.»

Not exact matches

«What that suggests is that this approach really gives us broad spectrum protection, and could serve as a basis for an effective pre-pandemic vaccine.»

To fund the new approach to the work, tenOever contacted the Army Research Office, which sponsors new technology for vaccine development.

Researchers for the past decade have focused on the T cell approach, based on studies showing that monkeys receiving such vaccines against simian immunodeficiency virus, related to HIV, lived longer or had lower viral levels than usual.

Vaccines 2.0 Rather than take Han's broader approach, Stanford University's Mark Davis, director of the Institute for Immunity, Transplantation and Infection, is focusing on unraveling one specific piece of the puzzle: the immune response to flu vaccination.

«We think we can use our molecular, rational design approaches to make a better flu vaccine for people who really need it,» says study leader Andrew Pekosz, PhD, an associate professor in the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health.

Throughout the company's trials the FDA has been on alert for signs that a patient could have a bad reaction as a result of this vaccine - making approach.

The advantage of Novavax's approach is that a vaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine Researchvaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine ResearchVaccine Research (CVR).

Other scientists are using multi-omic approaches for preventive medicine, for example, to be more effective and efficient in vaccine development.

A new approach to the live flu vaccine would be particularly advantageous right now after the Centers for Disease Control and Prevention stopped recommending use of the live attenuate flu vaccine, FluMist ® earlier this year.

The mRNA vaccine approach has other advantages, Weissman added: «If a vaccine is effective after just a single immunization, the infrastructure needed for its administration can be much simpler.

Phages would require a less traditional approach to get official approval, such as the annual process for influenza vaccines in which manufacturers secure approval of new formulas based on the flu bug that is going around that year, instead of conducting big clinical trials every time.

«The DOD brings a different, niched approach to international AIDS vaccine development that neither the NIH nor the [Centers for Disease Control and Prevention] has picked up.»

Therefore, the most logical approach for protecting threatened carnivores from canine distemper virus may be to target the vaccine on the endangered species itself.»

The approach may be useful to devise vaccines for other human pathogenic viruses, he says.

«This nanoformulation approach allows us to make vaccines against new diseases in only seven days, allowing the potential to deal with sudden outbreaks or make rapid modifications and improvements,» says Daniel Anderson, an associate professor in MIT's Department of Chemical Engineering and a member of MIT's Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES).

With this approach if validated for other vaccines, we only need to wait for a week,» says researcher Ali Harandi, who heads the participation of Sahlgrenska Academy and University of Gothenburg in the project.

For example, although early clinical trials of Listeria - based vaccines have shown that the neutralized bacterium produces only mild flulike symptoms in human patients with cervical cancer, the various methods of genetically disarming the bacteria should be explored to find the safest approach for people gravely ill with pancreatic cancer, because these patients are likely to already have weak immune systeFor example, although early clinical trials of Listeria - based vaccines have shown that the neutralized bacterium produces only mild flulike symptoms in human patients with cervical cancer, the various methods of genetically disarming the bacteria should be explored to find the safest approach for people gravely ill with pancreatic cancer, because these patients are likely to already have weak immune systefor people gravely ill with pancreatic cancer, because these patients are likely to already have weak immune systems.

This approach could be especially useful for delivering HIV vaccines and for stimulating the body's immune system to attack tumors, says Irvine, who is also a member of MIT's Koch Institute for Integrative Cancer Research.

«We have been struggling to use traditional vaccine - development approaches with these big pathogens,» says Julie Louise Gerberding, president of the vaccine division at Merck and former director of the US Centers for Disease Control and Prevention.

For 30 years, researchers have struggled to determine which immune responses best foil HIV, information that has guided the design of AIDS vaccines and other prevention approaches.

In the future, researchers hope to find new candidates for antibody vaccines by building on the success of the T cell approach or to replace it if it fails.

The vaccine is a «very novel approach for the treatment of obesity,» says Matthias Tschöp, an obesity researcher at the University of Cincinnati in Ohio.

The Transcriptomics Core Facility supports a systems biology approach in vaccine development focusing on the identification of transcriptomic correlates of vaccine immunogenicity and efficacy for a range of novel and licensed vaccines using PBMC or whole - blood and BAL fluid samples.

Extending cytokine / chemokine profiling platform (UNISI): Improvement of currently available services will be particularly focused on the optimisation of cytokine profiling for vaccine relevance using a systems biology approach.

Vinetz said the next step will be to begin exploiting the genomic information «for vaccine and diagnostics development, experimental approaches to understanding mechanisms of disease pathogenesis and how Leptospira persist in the environment, all critical for developing new public health interventions aimed at reducing the global impact of this important but neglected zoonotic disease.»

For their pioneering discoveries in chemistry and parasitology, and personal commitments to translate these into effective chemotherapeutic and vaccine - based approaches to control malaria - their collective work will impact millions of lives globally particularly in the developing countries.

Research will aim to improve the predictive value of animal models for vaccine evaluation, provide consultancy on the selection of appropriate models, and develop innovative approaches to characterise in vivo antigen behaviour and host responses whilst reducing animal use.

Results will be compared with new ex vivo / in vitro approaches for testing innate and adaptive responses induced by vaccine antigens.

«Nevertheless, this is a potentially exciting finding and it is possible that nivolumab, most likely in combination with other approaches such as therapeutic vaccines, may have a role in the eventual discovery of a cure for HIV.»

Douglas J. Schwartzentruber and colleagues at The University of Texas MD Anderson Cancer Center demonstrate that patients with metastatic melanoma receiving high doses of interleukin - 2 (IL - 2) plus a gp100 peptide vaccine had significant improvement in overall clinical response, providing further validation for vaccine approaches to cancer treatment.

The integrated production platform aims to produce and purify these proteins using a combination of engineered microbial cell factories and flexible approaches for purification to accommodate different vaccines and future candidates.

Ertl's research centers on developing vaccines for an array of diseases and conditions — including AIDS and some forms of cancer — not typically considered to be treated using this approach.

VAC2VAC stands for «Vaccine batch to vaccine batch comparison by consistency testing» and has the objective to deliver a proof of concept of consistency approach for batch release testing of established vaccines using sets of in vitro and analytical mVaccine batch to vaccine batch comparison by consistency testing» and has the objective to deliver a proof of concept of consistency approach for batch release testing of established vaccines using sets of in vitro and analytical mvaccine batch comparison by consistency testing» and has the objective to deliver a proof of concept of consistency approach for batch release testing of established vaccines using sets of in vitro and analytical methods.

The initiative aims to provide the data to support the «consistency approach» for quality control of established vaccines.

«With diseases spread by biting insects, such as Zika, standard quarantine measures are useless, so stopping an outbreak in its tracks requires a vaccine - led approach, as we are currently seeing carried out for Zika's relative, yellow fever, in Angola and neighbouring countries.

More specifically it is a wide - ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.

Nevertheless, this approach offers promise in the search for an eventual cure for HIV, probably in combination with other interventions such as vaccines.

This finding suggests that the typical approach to vaccines for treatment of cancer or AIDS is not likely to produce the desired result.

In a way, developing a vaccine for allergies requires the opposite approach to a vaccine against disease.

The genome sequence provides a fast track approach to finding vaccine candidates for a disease that had frustrated researchers for decades.

Using a bottom - up approach, the needs and priorities regarding European vaccine R&D were identified through a series of stakeholder consultations and workshops, and translated into a proposal for the establishment of a European Vaccine Research & Development Infrastructure vaccine R&D were identified through a series of stakeholder consultations and workshops, and translated into a proposal for the establishment of a European Vaccine Research & Development Infrastructure Vaccine Research & Development Infrastructure (EVRI).

Picking vaccine candidates from the entire repertoire of genes for an organism «will probably be the only approach used to find vaccines in the future, because the technique is so powerful and so fast,» says Rappuoli.

Current immunotherapy approaches for melanoma fall into seven main categories: checkpoint inhibitors, oncolytic virus therapies, cancer vaccines, adjuvant immunotherapy, adoptive cell therapy, monoclonal antibodies, and cytokines.

Therefore the group: i) characterizes the specificity of these antibody responses to identify relevant targets for a vaccine; ii) developes new approaches to test antibody responses; and iii) adoptes the immunological analysis in preclinical (in rabbits and macaques) and clinical vaccines studies to identify predictive signatures for the development and prioritization of new HIV - 1 vaccine candidates.

«The data from this study show the promise of vector - mediated gene transfer as an approach for immunization,» says Pat Fast, chief medical officer at the International AIDS Vaccine Initiative.

We have addressed adaption to the host, to antibiotics and to vaccine pressure, most recently developing new bacterial genome - wide association approaches to identify genetic determinants responsible for this adaptation.

Overall, this study both identifies specific antigen combinations for high - priority clinical testing and establishes a generalizable approach that is more likely to produce effective vaccines.